Clinical Trial Update: JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing JK-1201I versus Topotecan in relapsed extensive-stage small cell lung cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• JK-1201I
• Topotecan (topotecan)

Snippet

Sponsor: JenKem Technology Co., Ltd. | Conditions: Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING